chrisvoncsefalvay/vaers-outcomes huggingface dataset:
chills; This spontaneous case was reported by a patient and describes the occurrence of CHILLS (chills) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 026B21A and 001B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 10-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 07-Apr-2021, the patient experienced CHILLS (chills). At the time of the report, CHILLS (chills) outcome was unknown.            No concomitant medication was reported.  Treatment information not provided.  Action taken with mRNA-1273 in response to the events was not applicable.   This case was linked to MOD-2021-155013 (Patient Link).
Swollen, red, hot to the touch hard lump that persisted for 2.5 weeks. Became itchy and skin peeled.
COVID 19; COVID 19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 51-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), as dose 2 (booster), single (Batch/Lot number: unknown), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Known allergies: Sulfa" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Covid-19 vaccine janssen ("DOSE UNKNOWN Single; Vaccine location: Left arm.). The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 05May2022, outcome "not recovered" and all described as "COVID 19". The patient underwent the following laboratory tests and procedures: COVID-19: Negative; Positive. Therapeutic measures were taken as a result of drug ineffective, covid-19. Clinical course: Patient wasn't taken any medication in past 2 weeks. The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Rash on R/L face, nare with swelling, couple breaths. H/O egg allergy. ZYRTEC/BENADRYL and allergy referred with EPI PEN Jr. Rx for use with anaphylaxis.
After the first dose, I began itching on my right side near my waist to the point that hives and red skin appeared. After the second dose, I began itching and developing hives all over my body.
Approximately 3 months after my 4th dose vaccination I contracted COVID-19 and had the following symptoms: Cough, Sore Throat, Congestion. I called my Doctor and she prescribed me with an Antiviral medication for 5 days (4tabs/2x per day for 5 days). As of today 07/15/2022 I am feeling so much better now and all of my symptoms are gone.
tingling; This is a spontaneous report from a contactable consumer (patient). This consumer reported similar events for two patients. This is first of 2 reports. A 67-year-old female patient received BNT162B2 (Pfizer-Biontech COVID-19 vaccine, Solution for injection, Lot number: EL9265, Expiry Date: Unknown) intramuscular in left arm on 07Feb2021 as a single dose for COVID-19 immunization. Medical history included ongoing Lupus. She stated that it was a mild form of it. She said that she was diagnosed in the 1990's, around 1996, but she knows that she has had it since she was a kid. Patient also had a cancer (from Nov2012 to Jan2013) and underwent a surgery to remove the cancer. She had a Lumpectomy. Patient was not taking other products. Caller was a consumer that was calling about Covid-19 vaccine and said that she had a question about a side effect she was having. The caller said that she noticed the tingling the day of the injection in the evening on 07Feb2021. She was having tingling in her calf down to the bottom of her foot but stated that it is mostly on the bottom of her foot and just on the left foot. Caller stated that she felt like it was going to sleep. Caller wanted to know was this a known side effect. She did not know if it was common or not. Caller reported that her husband (age 66) experienced tingling too, but not sure what area. Her daughter knew of someone who had the tingling as well, she was much older (84-year-old). Caller stated that she was transferred from another department that obtained her symptom information, Pfizer COVID-19 vaccine's lot number and her age. Offered to transfer call back but caller refused.   There was no one present. Outcome of the event was not recovered.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021203719 same reporter/drug/AE with different patient
Within a minute of receiving the vaccine, my daughter fainted and had a short seizure. She did not hit her head because I was able to help her on her way down - it was a ver small room with 3 people in it. The pharmacist was there and he said it was a seizure, she just jerked her chin up, sharply 3 or 4 times. She laid on the ground for about five minutes, then sat on the ground, then sat in a chair for a total of about 20 minutes. She felt dizzy and nauseated for about 15 minutes after. She drank a juice and felt better so we drove home, no other symptoms since.
Prior to receiving the vaccine I had never had skin issues. If I had a skin injury it healed quickly. After the vaccine I had a minor burn on my hand and shortly afterward I noticed a scaly patches along the  path of the burn. I also had a squamous cell carcinoma removed from my leg and it also developed a hard scaly patches around it. I saw the dermatologist who did a biopsy and it was Lichen Planus which is an rare autoimmune disease. It has continued to appear on my arms and legs.  I need to know if other recipients of the vaccine have reported developing Lichen planus. I also need to know if I get the booster will it worsen the current status.
This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 42 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 21Nov2021 (Lot number: FJ8757) at the age of 42 years as dose 2, single for Covid-19 immunisation. Relevant medical history included: "Mild depression" (unspecified if ongoing); "bariatric surgery", start date: 2015 (unspecified if ongoing); "bariatric surgery", start date: 2021 (unspecified if ongoing); "thyroid problems" (unspecified if ongoing); "Covid" (unspecified if ongoing), notes: if Covid prior vaccination: yes. Concomitant medication(s) included: SYNTHROID; LEXAPRO. Vaccination history included: Bnt162b2 (previous dose product: COVID-19, previous  dose brand: Pfizer, previous  dose brand unknown: False, previous  dose lot number: FF2593, previous  dose lot unknown: False, previous  dose administration date: 30Oct2021 previous  dose dose number: 1, previous  dose vaccine location: Left arm), administration date: 30Oct2021, when the patient was 41 years old, for Covid-19 immunization. The following information was reported: PANIC ATTACK (hospitalization, disability) with onset 01Dec2021, outcome "not recovered", described as "Severe panic attacks"; SUICIDAL IDEATION (hospitalization, disability, medically significant) with onset 01Dec2021, outcome "not recovered", described as "suicide thoughts"; EMOTIONAL DISORDER (hospitalization, disability) with onset 01Dec2021, outcome "not recovered", described as "emotional breakdowns"; NERVOUSNESS (hospitalization, disability) with onset 01Dec2021, outcome "not recovered", described as "Nervous around people and big groups"; DIARRHOEA (hospitalization, disability) with onset 01Dec2021, outcome "not recovered", described as "diarrhea in nervous situations"; ANXIETY (hospitalization, disability) with onset 01Dec2021, outcome "not recovered", described as "severe anxiety"; CRYING (hospitalization, disability) with onset 01Dec2021, outcome "not recovered", described as "Crying episodes"; LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (hospitalization, disability) with onset 01Dec2021, outcome "not recovered", described as "Missed several weeks of work. Can't handle any adult responsibilities". The patient was hospitalized for emotional disorder, diarrhoea, anxiety, crying, loss of personal independence in daily activities (hospitalization duration: 10 day(s)). The events "severe panic attacks", "suicide thoughts", "emotional breakdowns", "nervous around people and big groups", "diarrhea in nervous situations", "severe anxiety", "crying episodes" and "missed several weeks of work. can't handle and adult responsibilities" were evaluated at the physician office visit and emergency room visit. Therapeutic measures were taken as a result of panic attack, suicidal ideation, emotional disorder, nervousness, diarrhoea, anxiety, crying, loss of personal independence in daily activities. The patient was not Covid tested post vaccination.
Narrative:  67 yo M with C4 ASIA B SCI since 2007 and history of recurrent nephrolithiasis (9 URS since 2015). Patient was admitted to the Spinal Cord Unit from an outside post-acute facility. The MD ordered the 1st dose of Pfizer COVID-19 to be given before the patient went to surgery on 3/24/21 at 1300hr. No reactions noted before or after surgery. On 3/25/21, a fax was received with patients immunizations record from the post-acute facility he was admitted from. The patient already received 2 doses of Moderna (01/05/21 and 01/27/21). MD informed. Provider disclosed to patient that a 3rd vaccine was given. 2nd Pfizer vaccine order canceled. Patient's immunization package updated with 1/6/21 and 1/7/21 outside COVID-19 vaccinations. Staff continue to monitor patient for any changes in condition. No patient harm.
Body felt numb; Swelling of feet; Felt "bad all over"; Extremely cold; Mind "wasn't clear"; Hardness at injection site; Itchiness at injection site; Fatigue; Chills; This spontaneous case was reported by a consumer and describes the occurrence of HYPOAESTHESIA (Body felt numb), PERIPHERAL SWELLING (Swelling of feet), MALAISE (Felt "bad all over"), NASOPHARYNGITIS (Extremely cold) and FEELING ABNORMAL (Mind "wasn't clear") in a 90-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032L203) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Thyroid disorder, Hypertension and Diabetes.   On 19-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 20-Feb-2021, the patient experienced HYPOAESTHESIA (Body felt numb), PERIPHERAL SWELLING (Swelling of feet), MALAISE (Felt "bad all over"), NASOPHARYNGITIS (Extremely cold), FEELING ABNORMAL (Mind "wasn't clear"), VACCINATION SITE INDURATION (Hardness at injection site), VACCINATION SITE PRURITUS (Itchiness at injection site), FATIGUE (Fatigue) and CHILLS (Chills). At the time of the report, HYPOAESTHESIA (Body felt numb), PERIPHERAL SWELLING (Swelling of feet), MALAISE (Felt "bad all over"), NASOPHARYNGITIS (Extremely cold), FEELING ABNORMAL (Mind "wasn't clear"), VACCINATION SITE INDURATION (Hardness at injection site), VACCINATION SITE PRURITUS (Itchiness at injection site), FATIGUE (Fatigue) and CHILLS (Chills) had not resolved.            No concomitant medications reported by investigator o No treatment medications provided by the reporter.
Information has been received from a health professional concerning a 4-5 year old female patient who on 03-Sep-2003 was vaccinated with a dose of MMR vaccine live. On 07-Sep-2003, four days after vaccination, the patient developed a measles rash all over her body which lasted three to four days. It was noted that the patient recovered. Unspecified medical attention was sought. Additional information has been requested.
Pt recd immun 31JAN91 & had syncope rxn 30min p/vax responded to trendelenburg, 5FEB91 returned w/petechiae & leukopenia, dec platelets, dx acute myelocytic leukemia;
put this in previous spot......rash fast heartbeat light headedness confusion, went from almost no periods to long painful periods, tender breasts, breathing issues, depression, anxiety, mood swings, hot/cold flashes,
Day 3 post second vaccination patient experienced chest pain - admitted Hospital. Patient had chest pain , elevated Troponin and positive stress test. taken to the Cath Lab where "normal coronaries, normal LV function".
Report 2000033944-1 describes Guillian-Barre syndrome in an adult male (age not provided) who received an injection of hepatitis B vaccine (Engerix-B). Concurrent medical conditions and medications were not provided. The patient received his first injection of Engerix-B on 10/17/2000. Two days later, he experienced "excruciating" eye pain, loss of sensation in his hands and feet, loss of coordination, and pain and numbness of his entire arm. He was seen by a nerologist. MRI, unspecified laboratory analyses, unspecified x-rays, and lumbar puncture were performed; no results of these examinations were provided. The neurologist made a diagnosis of "inflammatory polyneuropathy combined with history of vaccine." The pt had not recovered as of 11/20/2000. He was scheduled to receive and unspecified an approximately 11/27/2000, the pt became paralyzed from the waist down. He was hospitalized and a diagnosis of Guillian-Barre syndrome was made. He received intravenous immunoglobulin with no effect. He then received plasmapheresis with some improvement. he relapsed and received additional plasmapherresis treatments. In total, he underwent plasmapheresis 13 times. The most recent information, received from the pt on 04/10/2001, indicated that he was back to work on a limited basis. He continued to have no sensation in his feet or fingertips. He was experiencing tingling of his right ear and back, and pain in his lower back, hips, and legs. As a result of the additional information received on 04/10/2001, this case has been reclassified as serious.
Information has been received from a 57 years old female patient of unknown age. No known history condition and drug allergies. On 20-JAN-2015, the patient was vaccinated with ZOSTAVAX (dose, frequency, lot # and expiration date unknown). The patient experienced slight headache at the time of getting the ZOSTAVAX injection on 20-JAN-2015. On an unknown date in 2015, she went to see her physician for her annual examination and her blood work testing (type unspecified) showed her hemoglobin levels were elevated as if her body was "fighting off an infection". The patient said she was feeling fine on 18-MAR-2015, but was concerned about the outcome of her "blood work" and was working with her physician to undergo further testing. At the time of reporting, the outcome of hemoglobin levels were elevated was unknown. Additional information has been requested.
History provided by his wife, as the patient is currently in the hospital.  Following the 2nd Moderna vaccine, he developed itchy bumps around his neck and torso, then spread to the rest of his body.   He developed blisters over his body.   He developed a sore throat and cough.  He was seen by Dr in the office twice, followed by a virtual appt,  He was treated with Ketoconazole for rash, and Amoxicillin for sore throat and cough.  .He was referred to a dermatologist and biopsy was performed.  Colobetazole topical was added.   His condition worsened, he could no swallow.  He was taken by ambulance to the ER on 3/18/2021 and he was admitted.     He is still in the hospital.  Previously he had moments of confusion, but now this is worse.
Extreme fatigue; extreme weakness; shaky and trembly; Loss of appetite; Weight loss; Some dizziness; light headedness; This is a spontaneous report from a contactable consumer, the patient. A 81-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3247) via an unspecified route of administration in the left arm on 21Jan2021 at 16:00 (at the age of 81-years-old) and second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9265) via an unspecified route of administration in the left arm on 12Feb2021 (at the age of 81-years-old) as a single dose for COVID-19 immunisation. Medical history included low back pain, cholesterol which was being watched and insomnia. The patient was not allergic to medications, food, or other products. Concomitant medications included montelukast sodium (SINGULAIR). Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 24Jan2021, the patient experienced extreme fatigue, extreme weakness, shaky, trembly, loss of appetite, weight loss (6 lbs in 2 weeks), some dizziness and light headedness. The patient had no fever or respiratory symptoms. The adverse symptoms lasted for 10 weeks. The event resulted in doctor or other healthcare professional office/clinic visit 4 times. Therapeutic measures were not taken as a result of the events. On an unknown date in 2021, the patient underwent chest X-RAY and multiple lab tests and the result was within normal range. The clinical outcome of the events of extreme fatigue, extreme weakness, shaky, trembly, loss of appetite, weight loss, some dizziness and light headedness were resolving at the time of this report.    No follow-up attempts are needed. No further information is expected.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 39-year-old male patient received BNT162b2 (BNT162B2), in Dec2021 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 39 years for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Asthma" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: Treatment of COVID-19. Therapeutic measures were taken as a result of drug ineffective, covid-19. The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received. Clinical course: Rebound Covid after taxing full course of Paxlovid.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
onset of mild photophobia, frontal h/a, nausea, fatigue, low grade fever 10 day p/vax;devel paresthesia, LE's & distal LE day 12;adm to hosp for hydration;spinal tap glucose 63, protein 83, WBC 20 s/p mono, 20% segs;RBC 12;transferred
The patient received her flu shot 8/29/2020 at around 3:36 pm. The patient reports warmth, redness, and swelling around the injection site on her right arm. The patient showed the local reaction to the dermatologist. Her dermatologist did not think that the reaction needed any treatment. I advised the patient to continue to keep an eye on the local reaction, and if it does not get better or if it gets worse, then I advised the patient to follow up with her physician.
swelling of 1 lymph node above the collar bone; This spontaneous case was reported by a consumer and describes the occurrence of LYMPHADENOPATHY (swelling of 1 lymph node above the collar bone) in a 45-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025J20A) for COVID-19 vaccination.     No Medical History information was reported.    On 13-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Feb-2021, the patient experienced LYMPHADENOPATHY (swelling of 1 lymph node above the collar bone). At the time of the report, LYMPHADENOPATHY (swelling of 1 lymph node above the collar bone) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medications details were not reported by the reporter. Treatment information not provided by the reporter.
Site: Bruising at Injection Site-Medium, Site: Pain at Injection Site-Medium, Site: Redness at Injection Site-Medium, Site: Swelling at Injection Site-Medium, Error: Wrong Route (SC, IM, etc.)
Information has been received on 02-JAN-2018 regarding a case in litigation from a lawyer concerning a male patient of unknown age. There was no information provided regarding the patient's concurrent conditions, medical history or concomitant medications. The patient's healthcare provider, recommended and/or prescribed ZOSTAVAX to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. On or about 16-NOV-2015, a pharmacist at a pharmacy administered the ZOSTAVAX (lot number, expiration, dose and route unknown) to the patient. On or about 27-MAR-2017, the patient was treated by a healthcare provider at a physician's office for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX, and suffered serious physical, emotional and economic damages as a result of the patient's injuries. As a direct and proximate result of the ZOSTAVAX, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; lost wages; loss of earnings capacity; and other losses and damages. The outcome of the events is not recovered. The causality of the events is related. Additional information has been requested.